Renal biopsy cell cycle proliferation (CCP) score to predict adverse surgical pathology in renal cell carcinoma.

Jeffrey J. Tosoian, Adam S. Feldman, Madeline R. Abbott, Rohit Mehra, Placede Tiemeny, J. Stuart Wolf, Shulin Wu, Steven Stone, Chin‐Lee Wu, Stephanie Daignault, Jeremy M. G. Taylor, Todd M. MorganJournal of Clinical Oncology 2020 · DOI

Abstract

747 Background: The role of renal mass biopsy (RMB) in risk stratifying patients with renal cell carcinoma (RCC) is unclear. We sought to determine whether the cell cycle proliferation (CCP) score from RMB can improve risk stratification of localized RCC. Methods: We identified patients with RCC who underwent RMB and subsequent partial/radical nephrectomy from 2000-2014. We used multivariable logistic regression to determine the association of patient-level variables and biopsy CCP score with adverse surgical pathology (Fuhrman grade 3-4, pT stage≥3, papillary type II histology, or evidence of metastasis at surgery). Effect size was estimated with odds ratios (OR) and discriminative performance with AUC. Results: Overall, 94 of 202 patients (46%) had adverse surgical pathology. On multivariable analysis, CCP score >0 was associated with 2.38-fold increased odds of adverse pathology (Table). Relative to the model omitting CCP score (AUC=0.70), the addition of CCP score as a continuous (AUC=0.731) or binary (AUC=0.730) variable yielded increased discriminative performance. Similar associations were observed in an analysis limited to patients with low-grade tumors on biopsy (bCCP: OR 2.44, p=0.024; cCCP: OR 1.57, p=0.11). In both models, increased lesion size on imaging was consistently associated with adverse pathology. Conclusions: Among patients with RCC, biopsy CCP score >0 was independently associated with adverse pathology, suggesting this classifier provides prognostic information beyond conventional pathologic data. Biopsy CCP score could be used to better guide patient-specific management.[Table: see text]
BibTeX
@article{tosoian2020renal,
  author = {Jeffrey J. Tosoian and Adam S. Feldman and Madeline R. Abbott and Rohit Mehra and Placede Tiemeny and J. Stuart Wolf and Shulin Wu and Steven Stone and Chin‐Lee Wu and Stephanie Daignault and Jeremy M. G. Taylor and Todd M. Morgan},
  title = {{Renal biopsy cell cycle proliferation (CCP) score to predict adverse surgical pathology in renal cell carcinoma.}},
  journal = {Journal of Clinical Oncology},
  year = {2020},
  doi = {10.1200/jco.2020.38.6\_suppl.747},
}

Loading related content...

Figure